A phase I/IIa clinical trial of third-generation autologous chondrocyte implantation (IK-01) for focal cartilage injury of the knee

Takehiko Matsushita; Tomoyuki Matsumoto; Daisuke Araki; Kanto Nagai; Yuichi Hoshino; Takahiro Niikura; Atsuhiko Kawamoto; Masahiro J Go; Shin Kawamata; Masanori Fukushima; Ryosuke Kuroda

doi:10.1016/j.asmart.2022.03.004

A phase I/IIa clinical trial of third-generation autologous chondrocyte implantation (IK-01) for focal cartilage injury of the knee

Asia Pac J Sports Med Arthrosc Rehabil Technol. 2022 Mar 28:28:6-12. doi: 10.1016/j.asmart.2022.03.004. eCollection 2022 Apr.

Affiliations

¹ Department of Orthopedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
² Foundation for Biomedical Research and Innovation at Kobe, Japan.
³ Foundation of Learning Health Society Institute, Nagoya, Japan.

Abstract

Background/objective: The purpose of this study was to report the outcomes of a clinical trial conducted in Japan to assess the safety and effectiveness of third-generation autologous chondrocyte implantation (ACI) using IK-01 (CaReS™), which does not require flap coverage, in the treatment of patients with focal cartilage injury of the knee.

Methods: This was an open label, exploratory clinical trial. Patients were enrolled between June 2012 and September 2016. The primary endpoint of the study was the International Knee Documentation Committee (IKDC) score at 52 weeks after implantation. The IKDC, Lysholm, and visual analog scale (VAS) scores were evaluated at the time of screening and at 4, 12, 24, 36, and 52 weeks after implantation. Improvements from the baseline scores were evaluated using the equation "(postoperative score) - (preoperative score)." Magnetic resonance imaging (MRI) was performed at 2, 12, 24, and 52 weeks after implantation, and MRI measurements were evaluated using T1 rho and T2 mapping.

Results: Nine patients were enrolled in this study and were examined for safety. Product quality did not satisfy the specification in one patient, and bacterial joint infection occurred in one patient. As a result, seven patients were included in the outcome analyses. The mean IKDC score significantly improved from 36.4 preoperatively to 74.1% at 52 weeks after implantation (p < 0.0001). The mean Lysholm and VAS scores also significantly improved from 39.6 to 57.4 to 89.6 and 22.9, respectively, after surgery. In the MRI evaluation, the T1 rho and T2 values of the implanted area were similar to those of the surrounding cartilage at 52 weeks after implantation.

Conclusions: Third generation ACI (IK-01) can be an effective treatment option for focal cartilage defects of the knee; however, surgeons must pay careful attention to the risk of postoperative joint infection.

Keywords: Autologous chondrocyte implantation; Knee; Third-generation.